Fasenra
Benralizumab
Why Fasenra Costs $2,836.00 Per Claim
Fasenra (Benralizumab) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $987.0M on this drug, covering 32,000 beneficiaries across 348,000 claims.
This drug is currently protected by patents expiring Nov 14, 2031. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Fasenra increased by +18.6% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Fasenra (Benralizumab) costs an average of $2,836.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $30,844.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
No, Fasenra is currently brand-only. Patent protection expires Nov 14, 2031, after which generic versions may enter the market.
Medicare Part D spent $987.0M on Fasenra, covering 32,000 beneficiaries across 348,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.